RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Puma Biotechnology Stock

Puma Biotechnology EBIT 2024

Puma Biotechnology EBIT

23.15 M USD

Ticker

PBYI

ISIN

US74587V1070

WKN

A1J643

In 2024, Puma Biotechnology's EBIT was 23.15 M USD, a -30.4% increase from the 33.27 M USD EBIT recorded in the previous year.

The Puma Biotechnology EBIT history

YEAREBIT (undefined USD)
2029e-
2028e-2.04
2027e3.57
2026e17.75
2025e19.24
2024e23.15
202333.27
202223.8
20211.3
2020-30.4
2019-37.9
2018-94.7
2017-292.4
2016-276.6
2015-240.3
2014-142.3
2013-54.8
2012-74.5
2011-10.2
2010-

Puma Biotechnology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Puma Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Puma Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Puma Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Puma Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Puma Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Puma Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Puma Biotechnology’s growth potential.

Puma Biotechnology Revenue, EBIT and net profit per share

DatePuma Biotechnology RevenuePuma Biotechnology EBITPuma Biotechnology Net Income
2029e168.3 M undefined0 undefined0 undefined
2028e204 M undefined-2.04 M undefined-2.5 M undefined
2027e209.1 M undefined3.57 M undefined2.5 M undefined
2026e209.41 M undefined17.75 M undefined10.34 M undefined
2025e211.85 M undefined19.24 M undefined9.89 M undefined
2024e222.33 M undefined23.15 M undefined12.96 M undefined
2023235.64 M undefined33.27 M undefined21.59 M undefined
2022228 M undefined23.8 M undefined0 undefined
2021253.2 M undefined1.3 M undefined-29.1 M undefined
2020225.1 M undefined-30.4 M undefined-60 M undefined
2019272.3 M undefined-37.9 M undefined-75.6 M undefined
2018251 M undefined-94.7 M undefined-113.6 M undefined
201727.7 M undefined-292.4 M undefined-292 M undefined
20160 undefined-276.6 M undefined-276 M undefined
20150 undefined-240.3 M undefined-239.3 M undefined
20140 undefined-142.3 M undefined-142 M undefined
20130 undefined-54.8 M undefined-54.7 M undefined
20120 undefined-74.5 M undefined-74.4 M undefined
20110 undefined-10.2 M undefined-10.2 M undefined
20100 undefined0 undefined0 undefined

Puma Biotechnology stock margins

The Puma Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Puma Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Puma Biotechnology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Puma Biotechnology's sales revenue. A higher gross margin percentage indicates that the Puma Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Puma Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Puma Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Puma Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Puma Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Puma Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Puma Biotechnology Margin History

Puma Biotechnology Gross marginPuma Biotechnology Profit marginPuma Biotechnology EBIT marginPuma Biotechnology Profit margin
2029e73.4 %0 %0 %
2028e73.4 %-1 %-1.23 %
2027e73.4 %1.71 %1.2 %
2026e73.4 %8.48 %4.94 %
2025e73.4 %9.08 %4.67 %
2024e73.4 %10.41 %5.83 %
202373.4 %14.12 %9.16 %
202275.83 %10.44 %0 %
202174.84 %0.51 %-11.49 %
202082.5 %-13.51 %-26.65 %
201986.45 %-13.92 %-27.76 %
201886.22 %-37.73 %-45.26 %
201779.78 %-1,055.6 %-1,054.15 %
201673.4 %0 %0 %
201573.4 %0 %0 %
201473.4 %0 %0 %
201373.4 %0 %0 %
201273.4 %0 %0 %
201173.4 %0 %0 %
201073.4 %0 %0 %

Puma Biotechnology Aktienanalyse

What does Puma Biotechnology do?

Puma Biotechnology Inc. is a biopharmaceutical company based in Los Angeles. It was founded in 2010 and initially focused on the development of innovative cancer treatments. Since then, the company has significantly expanded and now offers a wide range of products and services all centered around cancer treatment. The company's business model revolves around developing drugs that address the need for novel and effective therapies to treat cancer. Puma Biotechnology Inc. is a leading player in this field and has already brought several successful products to market. One of the company's most well-known cancer treatments is Neratinib (also known as Nerlynx), which is used to treat breast cancer. Nerlynx received FDA approval in July 2017. Puma Biotechnology Inc. was founded in 2010 by Alan H. Auerbach, who had previously founded the biopharmaceutical company Cougar Biotechnology and successfully sold it to Johnson & Johnson. The history of Puma Biotechnology Inc. is marked by continuous growth. After its founding, the company acquired exclusive rights to develop neratinib for the treatment of breast cancer. The company has since conducted numerous studies and collected clinical data to prove the efficacy and safety of Nerlynx. After years of research, the medication finally received FDA approval in 2017. Puma Biotechnology Inc. has expanded its offerings since its founding and now offers a wide range of products and services centered around cancer treatment. One of the company's main areas of focus is research and development of cancer treatments. Puma Biotechnology Inc. continuously works on developing new drugs and therapies for a variety of cancer types, including breast cancer, lung cancer, and leukemia. The company is also involved in the production and marketing of pharmaceuticals. Neratinib is the company's most well-known product, but Puma Biotechnology Inc. has also brought other cancer treatments to the market. Additionally, Puma Biotechnology Inc. offers a wide range of services in the field of cancer treatment. The company is involved in the development of diagnostics and preventative measures and also offers training and consultations for doctors and patients. Nerlynx is Puma Biotechnology Inc.'s most well-known product and is now distributed worldwide. The medication is an oral therapeutic used for the adjuvant treatment of early-stage HER2-positive breast cancer in adults following adequate standard adjuvant therapy. It is taken by women who have already undergone chemotherapy, surgery, and radiation therapy. Neratinib works to prevent cancer recurrences by targeting the HER2 receptor, which normally promotes cancer cell growth. The medication blocks these receptors and can therefore inhibit tumor growth. In addition, Puma Biotechnology Inc. has also brought other products to the market, including Ribociclib, which is used in combination with other medications to treat ER-positive, HER2-negative breast cancer. In conclusion, Puma Biotechnology Inc. is a unique and emerging company with a focus on cancer treatments. Since its founding in 2010, the company has become a leading player in cancer combat. Puma Biotechnology Inc. is involved in the development of innovative therapeutic approaches, has achieved numerous medical successes, and brought many promising medications to the market. With Nerlynx, the company has introduced an effective medication for the treatment of breast cancer, and its potential is far from being realized. The company will undoubtedly play an important role in the treatment of cancer in the future. Puma Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Puma Biotechnology's EBIT

Puma Biotechnology's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Puma Biotechnology's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Puma Biotechnology's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Puma Biotechnology’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Puma Biotechnology stock

How much did Puma Biotechnology achieve in EBIT for the current year?

In the current year, Puma Biotechnology has achieved an EBIT of 23.15 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Puma Biotechnology.

How has the EBIT of Puma Biotechnology developed in recent years?

The EBIT of Puma Biotechnology has increased by -30.395% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Puma Biotechnology?

The EBIT of Puma Biotechnology is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Puma Biotechnology pay?

Over the past 12 months, Puma Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Puma Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of Puma Biotechnology?

The current dividend yield of Puma Biotechnology is .

When does Puma Biotechnology pay dividends?

Puma Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Puma Biotechnology?

Puma Biotechnology paid dividends every year for the past 0 years.

What is the dividend of Puma Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Puma Biotechnology located?

Puma Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Puma Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Puma Biotechnology from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Puma Biotechnology pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Puma Biotechnology in the year 2023?

In the year 2023, Puma Biotechnology distributed 0 USD as dividends.

In which currency does Puma Biotechnology pay out the dividend?

The dividends of Puma Biotechnology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Puma Biotechnology

Our stock analysis for Puma Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Puma Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.